Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires F.D., C1199ABB, Argentina
NCT Number: NCT04843917
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Buenos Aires, Buenos Aires F.D., C1199ABB, Argentina
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. The Ministry of Health of the Nation, designed the "Strategic Plan for vaccination", which the first line being the health workers " The National Administration of Medicines, Food and Medical Technology authorized two emergency vaccines for administration, Sputnik V and Sinopharm vaccine. It is important to evaluate immunogenicity and its correlation with the long-term efficacy and safety profile of this vaccines.
Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine between the time before the first dose, and after 1 month, 6 months and 12 months after the completion of the immunization, depending on whether they have received the Sputnik V vaccine or the Sinopharm vaccine, and correlate the Immunoglobulin G levels with the presence of adverse events and infection with COVID-19 Methodology: Design: observational and analytical study of a prospective cohort of healthcare workers immunized with some COVID-19 vaccine. The presence of IgG will be determined qualitatively and quantitatively. The immunoglobulin G titer in each period will be compared globally and according to the type of vaccine administered.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
Time frame: 1 year
To assess the change in the levels of Immunoglobulin G (IgG) antibodies from baseline at 1 month, at 6 months and at 12 months after the completion of the immunization in health workers who received a COVID-19 vaccine
Time frame: 1 year
To correlate the Immunoglobulin G levels with the presence of adverse events and infection with COVID-19
Hospital Italiano de Buenos Aires
Other
Immunity Against the COVID-19 Vaccine in Healthcare Workers of Buenos Aires, Argentine.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04371432
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT05492552
COVID-19, Coronaviridae Infections
Coventry, West Midlands, United Kingdom
View Trial DetailsNCT07672626
Vaccine
Pizhou, Jiangsu, China
View Trial DetailsNCT05054621
COVID-19, Coronaviridae Infections
Taoyuan, Taiwan
View Trial Details